

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Complete if Known

Application Number	08/480,472
Filing Date	June 6, 1995
First Named Inventor	Sherrol McDonough
Art Unit	1631
Examiner Name	Marschel, A.
Attorney Docket Number	GP034-03.DV1

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
AM		WO-A-88 03957	06-02-1988	Gen-Probe Inc.	
AM		WO-A-93 04201	03-04-1993	Amoco Corp.	

Examiner Signature	<i>Edie Mansch</i>	Date Considered	6-26-05
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of

4

Application Number 08/480,472

Filing Date June 6, 1995

First Named Inventor Sherrol McDonough

Art Unit 1631

Examiner Name Marschel, A.

Attorney Docket Number GP034-03.DV1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AM		Brewer, et al., "Mechanistic Independence of Avian Myeloblastosis Virus DNA Polymerase and Ribonuclease H," Dec. 1974, J. Virol., 14(6):1494-1502, ASM, USA.	
		Champoux, et al., "Mechanism of RNA Primer Removal by the RNase H Activity of Avian Myeloblastosis Virus Reverse Transcriptase," Mar. 1984, J. Virol., 49(3):686-691, ASM, USA.	
		Collett, et al., "In Vitro Transcription of 70S RNA by the RNA-Directed DNA Polymerase of Rouse Sarcoma Virus: Lack of Influence by RNase H," Jan. 1976, J. Virol. 17(1):291-5, PMID: 54443, ASM, USA.	
		Crouch, R.J., "Ribonuclease H: from discovery to 3D structure," Sep. 1990, New Biol., 2(9):771-7, PMID: 2177653.	
		Day, R., "How to Write and Publish a Scientific Paper," 2nd Ed., Philadelphia: ISI Press, 1983, p.170.	
		Fahy, et al., "Self-sustained sequence replication (3SR): an isothermal transcription-based amplification system alternative to PCR," Aug. 1991, PCR Methods Appl., 1(1):25-33, PMID: 1842917.	
		Grandgenett, et al., "Different Mode of Action of Ribonuclease H in Purified alpha and alpha beta Ribonucleic Acid-Directed Deoxyribonucleic Acid Polymerase from Avian Myeloblastosis Virus" Aug. 25, 1974, J. Biol. Chem., 249(16):5148-5152, USA.	
		Kacian, et. al., "Synthesis of extensive, possibly complete, DNA copies of poliovirus RNA in high yields and at high specific activities," July 1976, Proc. Natl. Acad. Sci., 73(7):2191-2195, USA.	
		Kacian, et al., "Anticomplementary nature of smaller DNA produced during synthesis of extensive DNA copies of poliovirus RNA," October 1976, Proc. Natl. Acad. Sci., 73(10):3408-3412, USA.	
		Keller, et al., "Degradation of DNA RNA Hybrids by Ribonuclease H and DNA Polymerase of Cellular and Viral Origin," November 1972, Proc. Natl. Acad. Sci. 69(11):3360-3364, USA.	


Examiner Signature	<i>A. Marschel</i>	Date Considered	6-26-05
--------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of

4

Application Number

08/480,472

Filing Date

June 6, 1995

First Named Inventor

Sherrol McDonough

Art Unit

1631

Examiner Name

Marschel, A.

Attorney Docket Number

GP034-03.DV1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AM		Maniatis, et al., Molecular Cloning, 1982, Cold Spring Harbor, N.Y.: Cold Spring Harbor Press, pp. 128, 213-214.	
		Marcus, et al., "Reverse Transcriptase-Associated RNase H Activity II. Inhibition by Natural and Synthetic RNA," Sept. 1978, J. Virol. 27(3):576-581, ASM, USA.	
		Modak, et al., "Specific Inhibition of DNA Polymerase-Associated RNase H by DNA," Apr. 1977, J. Virol., 22(1):243-246, ASM, USA.	
		Moelling, K., "Characterization of reverse transcriptase and RNase H from friend-murine leukemia virus," Nov. 1974, Virology, 62(1):46-59, PMID: 4138103.	
		Myers, et al., "RNA primer used in synthesis of anticomplementary DNA by reverse transcriptase of avian myeloblastosis virus," March 1980, Proc. Natl. Acad. Sci., 77(3) 1316-1320, USA.	
		Myers, et al., "Sodium pyrophosphate inhibition of RNA-DNA hybrid degradation by reverse transcriptase," Nov. 1978, Proc. Natl. Acad. Sci., 75(11):5329-5333, USA.	
		Myers, et al., "Synthesis of full-length DNA copies of avian myeloblastosis virus RNA in high yields," July 1977, Proc. Natl. Acad. Sci., 74(7):2840-2843, USA.	
		Resnick, et al., "Involvement of Retrovirus Reverse Transcriptase-Associated RNase H in Initiation of Strong Stop (+) DNA Synthesis and the Generation of the Long Terminal Repeat," Sept. 1984, J. Virol. 51(3):813-821, ASM, USA.	
		Rogall, et al., "Differentiation of Mycobacterium species by direct sequencing of amplified DNA," Sept. 1990, J. Gen. Microbiol., 136(Pt. 9):1915-1920, PMID: 2283506.	
		Srivastava, et al., "Reverse transcriptase-associated RNase H. Part IV. Pyrophosphate does not inhibit RNase H activity of AMV DNA polymerase," Dec. 14, 1979, Biochem. Biophys. Res. Commun., 91(3):892-899, PMID: 93479.	


Examiner
Signature*Adin Marschel*Date
Considered

6-26-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	08/480,472
Filing Date	June 6, 1995
First Named Inventor	Sherrol McDonough
Art Unit	1631
Examiner Name	Marschel, A.
Attorney Docket Number	GP034-03.DV1

Sheet 4

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AM		Wintersberger, U., "Ribonucleases H of retroviral and cellular origin," 1990, Pharmacol. Ther., 48(2):259-280 PMID: 1963496.	
AM		Wohrl, et al., "Mutations of a conserved residue within HIV-1 ribonuclease H affect its exo- and endonuclease activities," Aug. 5, 1991, J. Mol. Biol., 220(3):801-818, PMID: 1714505.	

Examiner
Signature*Austin Marschel*Date
Considered

6-26-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
213/067SERIAL NO.
08/479,105APPLICANT:
Diane L. McAllister et al.FILING DATE:
June 6, 1995GROUP:
1631Citations for Divisional Application
Serial No. 08/480,472, Filed June 6, 1995
Attorney Docket No. GP034-03.DV1
Page 1 of 3

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
AM	AA 4 6 8 3 2 0 2	07/28/87	Mullis			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
AM	AB 9 1 0 1 3 8 4	07.02.91	PCT/WO (Kacian and Fultz)			
	AC 0 4 0 8 2 9 5	16.01.91	EPO (Kacian and Fultz)			
	AD 0 4 3 9 1 8 2	25.01.91	EPO (Backman et al.)			
	AE 9 2 0 7 9 5 7	14.05.92	EPO (Kimino et al.)			
	AF 9 2 2 2 6 6 3	23.12.92	WO/PCT (Schuster and Berninger)			
	AG 0 5 8 7 2 6 6	06.05.93	EPO (Kacian et al.)			
	AH 5 5 9 7 0 9	24.02.88	Canada (Malek and Davey)			
	AI 0 3 2 9 8 8 2	30.08.89	EPO (Davey and Malek)			
	AJ 0 3 7 3 9 6 0	20.07.90	EPO (Gingeras)			
	AK 8 7 0 6 2 7 0	22.10.87	WO/PCT (Chu et al.)			
	AL 8 9 0 1 0 5 0	09.02.89	WO/PCT (Burg et al.)			
	AM 9 0 1 4 4 3 9	29.11.90	WO/PCT (Kramer and Lizard)			
	AN 0 3 0 0 7 9 6	25.01.89	EPO (Becker et al.)			
	AO 8 8 1 0 3 1 5	29.12.88	WO/PCT (Gineras et al.)			
	AP 0 4 6 1 0 4 5	07.06.91	EPO (Guesdon and Thierry)			
	AQ 2 6 5 9 0 8 6	02.03.90	France (Brisson-Noel)			
	AR 2 6 5 1 5 0 5	06.09.89	France (Guesdon et al.)			
	AS 9 1 1 5 6 0 1	04.04.91	WO/PCT (Shuldiner and Roth)			
	AT 0 3 9 8 6 7 7	16.05.90	EPO (Wirth and Patel)			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	AA	Bethesda Research Laboratories Catalogue and Reference Guide, Bethesda Research Laboratories, Bethesda, MD (1988) p. 37
	AB	Boh et al., "A general strategy for cloning double-stranded RNA: nucleotide sequence of the Simian-11 rotavirus gene 8," <u>Nucleic Acids Research</u> 10:7075 (1982)
	AC	Cashdollar et al., "Cloning the Double-stranded RNA Genes of a Reovirus: Sequence of the cloned S2 gene," <u>Proc. Natl. Acad. Sci. USA</u> 79:7644-7648 (1982)

EXAMINER:

Adam Mansch

DATE CONSIDERED:

6-26-05

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
213/067SERIAL NO.
08/479,105


APPLICANT:

Diane L. McAllister et al.

FILING DATE:
June 6, 1995

GROUP:

1631

Citations for Divisional Application
Serial No. 08/480,472, Filed June 6, 1995
Attorney Docket No. GP034-03.DV1
Page 2 of 3

AM	AD	Cox et al., "The 16S ribosomal RNA of <i>Mycobacterium leprae</i> contains a unique sequence which can be used for identification by the polymerase chain reaction," <u>J. Med. Microbiol.</u> , 35:284-290 (1991)
	AE	European Search Report for Application No. 90307503.4 dated 7/2/1991 Not a patent
AM	AF	Golomb and Grandgenett, "Endonuclease Activity of Purified RNA-directed DNA Polymerase from Avian Myeloblastosis Virus," <u>The Journal of Biological Chemistry</u> 254:1606-1613 (1979)
	AG	Grachev et al., "Oligonucleotides complementary to a promoter over the region -8... +2 as transcription primers for <i>E. coli</i> RNA polymerase," <u>Nucleic Acids Research</u> 12:8509 (1984)
	AH	Guatelli et al., "Isothermal, <i>in vitro</i> amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication," <u>Proc. Natl. Acad. Sci. USA</u> 87:1874-1878 (1990)
	AI	Gubler, <u>Guide to Molecular Cloning Techniques</u> , Academic Press, NY, NY (1987) p. 330
	AJ	Hayes, "The Genetics of Bacteria and their Viruses," John Wiley & Sons Inc., 2nd ed.:239-257, New York (1964)
	AK	Joyce, "Amplification, Mutation and Selection of Catalytic RNA," <u>Gene</u> , 82:83-87 (1989)
	AL	Khorana, "Total Synthesis of a Gene," <u>Science</u> , 203:614-25 (1979)
	AM	Krug and Berger, "Ribonuclease H activities associated with viral reverse transcriptases are endonucleases," <u>Proc. Natl. Acad. Sci. USA</u> 86:3539-3543 (1989)
	AN	Krug & Berger, "First-Strand cDNA Synthesis Primed with Oligo(dT)," (Methods in Enzymology) <u>Guide to Molecular Cloning Techniques</u> , Berger and Kimmel, eds., (Academic Press:NY, 1987) Vol. 152, pp. 316-325
	AO	Kupper et al., "Promoter-dependent transcription of TRNA ₁ genes using DNA fragments produced by restriction enzymes," <u>Proc. Natl. Acad. Sci. USA</u> 72:4754 (1975)
	AP	Kwoh et al., "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format," <u>Proc. Natl. Acad. Sci. USA</u> 86:1173-1177 (1989)
	AQ	Leis et al., "Mechanism of Action of the Endonuclease Associated with the $\alpha\beta$ and $\beta\beta$ Forms of Avian RNA Tumor Virus Reverse Transcriptase," <u>Journal of Virology</u> 45:727-739 (1983)
	AR	Lomonosoff, et al., "The Location of the First AUG Codons in Cowpea Mosaic Virus RNAs," <u>Nucleic Acids Research</u> , 10,16:4861-72 (1982)
	AS	Lowary et al., "A Better Way to Make RNA for Physical Studies," <u>Structure & Dynamics of RNA</u> , Nato ASI Series Knippenberg, eds. (New York: Plenum Press, 1986) Vol. 110
	AT	Milligan et al., "Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates," <u>Nucleic Acids Research</u> 15:8783-98 (1987)
	AU	Mullis and Faloona, "Specific Synthesis of DNA <i>in Vitro</i> via a Polymerase-Catalyzed Chain Reaction," <u>Methods in Enzymology</u> , 155:355-349 (1987)
	AV	Murakawa et al., "Direct Detection of HIV-1 RNA from AIDS and ARC Patient Samples," <u>DNA</u> , 7:287-295, 1988
	AW	Okayama and Berg, "High-Efficiency Cloning of Full-Length cDNA," <u>Molecular and Cellular Biology</u> 2:161-170, 1982.
V	AX	Oyama et al., "Intrinsic Properties of Reverse Transcriptase in Reverse Transcription," <u>J. Biol. Chem.</u> , 264:18808-18817 (1989)

EXAMINER:

Ardin Marshall


DATE CONSIDERED:

6-26-05

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
213/067SERIAL NO.
08/479,105APPLICANT:
Diane L. McAllister et al.FILING DATE:
June 6, 1995GROUP:
1631Citations for Divisional Application
Serial No. 08/480,472, Filed June 6, 1995
Attorney Docket No. GP034-03.DV1
Page 3 of 3

AM	AY	Rossi et al., "An Alternate Method for Synthesis of Double-stranded DNA segments," <u>L. Biol. Chem.</u> 257:9226 (1982)
	AZ	Stent, "Molecular Biology of Bacterial Viruses," W.H. Freeman & Company, 157-63, San Francisco (1963)
	BA	Tyagi et al., <u>Trop. Med. Parasitol.</u> 41:294-296 (1990)
	BB	Watson and Crick, "Molecular Structure of Nucleic Acids," <u>Nature</u> , April 25, 1953, p. 737
	BC	Watson & Crick, "Genetical Implications of the Structure of Deoxyribonucleic Acid," <u>Nature</u> , 171:964-967 (1953)
	BD	Wilk et al., "Backbone-modified oligonucleotides containing a butaneodiol-1,3 moiety as a 'vicarious segment' for the deoxyribosyl moiety - synthesis and enzyme studies," <u>Nucleic Acids Research</u> 18:2065-2068 (1990)
✓	BE	Zoller and Smith, "Oligonucleotide-Directed Mutagenesis of DNA Fragments Cloned into M13 Vectors," <u>Methods in Enzymology</u> , 100:468-500 (1983)

EXAMINER:

Ardin Marshall

DATE CONSIDERED:

6-26-05

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB-08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
in a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number.				Complete if Known	
Substitute for form 1449/PTO				Application Number	08/480,472
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	June 6, 1995
(Use as many sheets as necessary)				First Named Inventor	Sherrol H. McDonough
				Art Unit	1631
				Examiner Name	Marschel, A.
				Attorney Docket Number	GP034-03.DV1
Sheet	1	of	1		

[illegible]

Examiner Signature	<i>Ardis Marshall</i>	Date Considered	6-26-05
-----------------------	-----------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-8199 (1-800-786-9199) and select option 2.